60 Degrees Pharmaceuticals (SXTP) Q3 2024 Earnings
SXTP·Reported November 14, 2024·Before market open
60 Degrees Pharmaceuticals reported Q3 2024 revenue of $135.3K, missed analyst consensus of $250.0K by $114.7K. Diluted EPS came in at $-4.65, missed the $-3.00 consensus by $1.65.
Revenue
$135.3Kmissed by $114.7K
Consensus: $250.0KDiluted EPS
$-4.65missed by $1.65
Consensus: $-3.00
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about 60 Degrees Pharmaceuticals's Q3 2024 earnings report.
60 Degrees Pharmaceuticals (SXTP) reported Q3 2024 earnings on November 14, 2024 before market open.
60 Degrees Pharmaceuticals reported revenue of $135.3K and diluted EPS of $-4.65 for Q3 2024.
Revenue missed the consensus estimate of $250.0K by $114.7K. EPS missed the consensus estimate of $-3.00 by $1.65.
You can read the 10-Q periodic report (0001213900-24-098195) directly on SEC EDGAR. The filing index links above go to sec.gov.